Scarica l'app Stockscreener
98.61
2.93%
2.805
Pre-mercato:
94.21
-4.395
-4.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$95.80
Aprire:
$95.82
Volume 24 ore:
4.23M
Relative Volume:
1.17
Capitalizzazione di mercato:
$21.37B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-17.17
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
+1.17%
1M Prestazione:
-7.19%
6M Prestazione:
-43.90%
1 anno Prestazione:
-3.97%
Intervallo 1D:
$95.27
$99.88
Intervallo di 1 settimana:
$93.92
$100.25
Portata 52W:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
98.61 | 20.76B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors? - Yahoo Finance
Form 144 INSMED INC For: 22 June By Investing.com - Investing.com Canada
Michael Smith files Form 144 listing multiple INSM share sales (INSM) - Stock Titan
INSM Maintained by Evercore ISI Group -- Price Target Lowered to $160 - GuruFocus
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise? - Yahoo Finance
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
What's Driving Insmed's Recent Volatility - Kavout
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
Insmed Stockanalyst coverage and sector comparison at week’s end - AD HOC NEWS
Insmed Inc (MIL:1INSM) Stock Price, Trades & News - GuruFocus
InvestingPro’s Fair Value spotted Insmed’s 44% drop before it happened By Investing.com - Investing.com
Insmed Incorporated(NasdaqGS: INSM) dropped from NASDAQ-100 Index - marketscreener.com
Insmed slips as investors weigh recent analyst caution and launch expectations - Quiver Quantitative
Top Insmed (INSM) Competitors 2026 - MarketBeat
Insmed Inc (INSM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insmed Inc (INSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insmed Inc (INSM) Institutional Confidence - TradingKey
Insmed Inc (INSM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed Inc (INSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insmed Inc (INSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $243 - Moomoo
Mizuho cuts Insmed stock price target on volatility concerns - Investing.com UK
Mizuho cuts Insmed stock price target on volatility concerns By Investing.com - Investing.com Nigeria
Exome Asset Management LLC's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Sees Price Target Reduction Amid Market Sentiment Shift - GuruFocus
Monashee Investment Management LLC Acquires Shares of 50,000 Insmed, Inc. $INSM - MarketBeat
A Blueprint For Addressing Underserved Patient Populations - Clinical Leader
Nasdaq-100 Index® June 2026 Quarterly Changes - GlobeNewswire Inc.
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $214 - Moomoo
Insmed stock hits 52-week low at 90.85 USD By Investing.com - Investing.com Nigeria
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Insmed slides 7.9% as risk-off tape collides with pipeline-focused positioning ahead of TPIP data - Quiver Quantitative
[Form 4] INSMED Inc Insider Trading Activity - Stock Titan
Insmed stock hits 52-week low at 90.85 USD - Investing.com
Stock Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook - Investing.com UK
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook By Investing.com - Investing.com Australia
GW&K Investment Management LLC Reduces Position in Insmed, Inc. $INSM - MarketBeat
Axiom Investors LLC DE Has $44.53 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): pipeline update and growth story in rare diseases - AD HOC NEWS
INSM: Brensocatib’s stellar launch and expanding pipeline set the stage for sustained growth - TradingView
Insmed Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
INSM Maintained by JP Morgan -- Price Target Lowered to $179 - GuruFocus
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline - GuruFocus
William Lewis files Form 144 — INSM insider sale notice (INSM) - Stock Titan
Insmed Is Maintained at Overweight by JP Morgan - Moomoo
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):